Barinthus Bio Q2 2026: $59.6M Cash, VTP-1000 Enrollment Complete, Clywedog Merger on Track
BRNS is trading near its 52-week low of $0.512 (11% above the low) on light trading volume (0.1× avg).
Summary
Barinthus Bio posted Q2 2026 results with $59.6M in cash, completed enrollment in the VTP-1000 celiac disease trial, and confirmed the Clywedog merger is on track to close in H2 2026, with combined cash runway through 2027.
Key Events · Earnings and Guidance · BRNS
-
Q2 2026 Financial Results
Net loss of $10.6 million ($0.26/share) on reduced R&D spend of $3.9 million; cash and equivalents of $59.6 million as of June 30, 2026, providing at least 12 months of standalone runway.
-
VTP-1000 Enrollment Complete
Completed enrollment of all 42 planned subjects in the multiple ascending dose portion of the Phase 1 AVALON trial in celiac disease; topline data expected in Q4 2026.
-
Clywedog Merger Progress
Merger expected to close in H2 2026; combined company to be renamed Clywedog Therapeutics Holdings, trade as CLYD, and have cash runway through 2027 supported by OrbiMed and Torrey Pines.
-
Nasdaq Delisting Extension
Received extension until December 28, 2026, to regain compliance with the $1.00 bid price requirement; shares transferred to Nasdaq Capital Market effective July 2, 2026.
Analysis · BRNS · Life Sciences
With a net loss of $10.6 million, or $0.26 per share, and cash of $59.6 million, Barinthus Bio's Q2 2026 results provide at least 12 months of standalone runway. Enrollment is now complete in the multiple ascending dose portion of the Phase 1 AVALON trial for VTP-1000 in celiac disease, and topline data are expected in Q4 2026. The proposed reverse merger with Clywedog Therapeutics is progressing toward a close in the second half of 2026; the combined company will be renamed Clywedog Therapeutics Holdings and trade under the ticker CLYD, with an estimated cash runway through 2027. The stock remains under delisting pressure, with a Nasdaq extension until December 28, 2026, and a recent transfer to the Nasdaq Capital Market. These updates come against a backdrop of sharply reduced operating expenses and a strategic pivot to immunology and inflammation, making the upcoming data readout and merger completion critical catalysts for the company's survival and value proposition.
At the time of this filing, BRNS was trading at $0.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.3M. The 52-week trading range was $0.51 to $1.83. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.